Comparative Pharmacology
Head-to-head clinical analysis: CILOXAN versus ZYMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CILOXAN versus ZYMAR.
CILOXAN vs ZYMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription.
Ofloxacin is a fluoroquinolone antibacterial that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
1-2 drops in affected eye(s) every 2 hours while awake for 2 days, then every 4 hours for 5 days; or 1-2 drops 4 times daily for 7 days. Ointment: ½-inch ribbon into conjunctival sac 3 times daily for 2 days, then 2 times daily for 5 days.
1 drop instilled into the affected eye(s) every 2 hours while awake on Day 1, then 1 drop 4 times daily on Days 2 through 7.
None Documented
None Documented
Terminal elimination half-life approximately 4 hours in patients with normal renal function; extended to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 4.5 hours in adults, supporting twice-daily dosing for ocular infections.
Renal: 50-70% unchanged drug; biliary: 15-20% as metabolites; fecal: 20-35%
Renal excretion of unchanged drug accounts for approximately 70% of an administered dose; biliary/fecal excretion accounts for about 30%.
Category C
Category C
Fluoroquinolone Antibiotic (Ophthalmic)
Fluoroquinolone Antibiotic (Ophthalmic)